Skip to main content

LIVE

OverviewAnalystsInstitutionalElite HoldersEarningsNews
TYRA

Tyra Biosciences, Inc.

TYRA

NASDAQ·Healthcare·Biotechnology·Mkt cap $1.7B

$28.65

▲ +15.25%

P/E

-11.94

Mkt Cap

$1.7B

52-Wk Range

$11.70–$40.65

52-Week Range

$11.70 - $40.65

P/E

-11.94

Fwd P/E

-10.59

Beta

0.73

Div Yield

0.00%

Avg Vol

767.3K

Shares Out

53.7M

Mkt Cap

$1.7B

Price action

Price chart

Up 136.2% over the trailing year

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Proprietary SNAP platform enabling rapid iterative molecular design and optimization
  • Selective FGFR inhibitor approach reducing off-target toxicity compared to pan-FGFR inhibitors
  • Diversified pipeline across multiple cancer indications and genetic disorders with high unmet medical needs
  • Focused development strategy targeting genetically defined patient populations with validated biomarkers
▼

Bear Case

1 risk

  • Low volatility (beta 0.7).

Growth

Stable outlook

Advancement of TYRA-300 through clinical development for muscle invasive bladder cancer treatment

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Strong

+7.1% over 3m

Quality

Loss-making

Mixed fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Nov 4, 2026

“
Q3 26 RECAP

AUG 4, 2026

Reported EPS of -$0.69 vs -$0.65 consensus (-6.2% surprise).

EPS miss

EPS surprise · last 4Q

0 of 1 beats

Estimate

Actual

Q3 26

-6.2%

Revenue trend · last 8Q

—

—

—

—

—

—

—

—

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

Q2 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

View full earnings history →

Wall Street consensus

4 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

4

100%

Hold

0%

Sell

0%

Median Price Target

—

Latest: Jefferies · Aug 5, 2026

View full analyst page →

vs Industry

How TYRA stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.